BLAINVILLE, QC — Duchesnay, a Canadian specialty pharmaceutical company with a long-standing commitment to women's health, member of Duchesnay Pharmaceutical Group (DPG), announces the Canadian roll out of PrRingza, a new contraceptive vaginal system.
PrRingza is the result of a collaboration between Duchesnay and the Population Council, an international nonprofit research organization and the product developer. PrRingza is the only slow-release vaginal ring made of silicone design to be re-used for up to one year (13 menstrual cycles of 3 weeks in, 1 week out). PrRingza is a patient-controlled and reversible vaginal system not requiring insertion or removal by a clinician.
"Canadian women are seeking contraceptive options that reflect their diverse lifestyles and empower them to make informed choices on their own terms. For them to achieve that, we need to offer them a variety of innovative options to ensure that one will best fit their life," said Dr. Dre Diane Francoeur. "Any new contraceptive method is always welcome. This new contraceptive vaginal ring brings a new definition of autonomy with its convenience of only 1 ring per year supporting women's personal choice."
PrRingza is indicated for use by women of reproductive potential to prevent pregnancy. PrRingza has not been adequately studied in women with a Body Mass Index (BMI) > 29.0 kg/m.
The efficacy and safety of PrRingza for use in contraception were demonstrated in two pivotal clinical studies of 13-cycle duration. The most common adverse reactions (≥10%) observed in these clinical studies were headache, nausea, and vaginal discharge.
"PrRingza is an important new contraceptive option that provides bleeding patterns consistent with a planned withdrawal bleed, a priority for many women," said Dr. Cleve Ziegler, Director of Gynecology at the Jewish General Hospital, a McGill University affiliated teaching hospital. "With minimal monthly management and a single pharmacy visit per year, it likely supports women's adherence to their contraceptive choice. Women being in control of their contraception allows them to focus on their daily activities."
PrRingza delivers the first Canadian use of segesterone acetate, a new chemical entity, in the country. The flexible silicone ring releases a daily dose of 0.15 mg segesterone acetate, a novel non-androgenic progestin, and 0.013 mg ethinyl estradiol.
"Duchesnay is redefining innovation for Canadian women. As a Canadian company based in Quebec owning the rights in several countries for this new contraceptive vaginal system, with exception of the United States (where it is commercialized under another brand name), we are proud to make Canada the first country to launch PrRingzaTM, and lead the way for the world. PrRingza is a combination of unique features with a single pharmacy visit per year," said Édith Sirard, Director, Sales and Marketing, DPG. "This is reinforcing our commitment to advancing women's health and a significant step forward in expanding access to meaningful innovative solutions that prioritize women's evolving needs in 2026 and beyond."
With the introduction of PrRingza, Duchesnay establishes itself as an emerging leader in contraception through its commitment to expanding access to new therapeutic options and advancing solutions that meet the diverse needs of women across Canada.
